Skanray is an internationally recognized Medical Equipment Manufacturer (Retail/OEM) from India in the field of Diagnostic Medicine and Critical Healthcare, with an international reach in production and R&D. Skanray Technologies IPO will hit the market in 2021.
Table of Contents
About
Skanray Technologies is a globally recognised med-tech business with specialised innovation teams in Europe and India, as well as global production sites in India, Italy, and Latin America. Production, Design & Development, Quality Control, and Quality Assurance departments are all based in India.
Patents
Skanray currently has more than 80 patents in 50 different sections of CE/FDA certified high-end medical equipment that serve to all aspects of healthcare delivery.
This is including to Diagnostic X-Ray devices, Surgical C-Arms, Dental Radiography Devices, Patient Monitoring Systems, Defibrillators, Critical Care Ventilators, Anaesthesia Workstations, ECG Devices, and Central Nursing Devices.
Products
Skanray creates products that meet FDA, UL, and CE standards in the United States. The facilities have ISO 9001, ISO 13485: 2003, ISO 14001: 2004 and OHSAS 18001 certifications.
Skanray is a real worldwide firm that focuses on supplying premium goods and tries to enhance their excellent healthcare with a track record of over 100,000 installations in such a wide range of equipment.
Foot prints
Skanray delivers Total Healthcare Solutions to hospitals and clinics by bringing in the finest of design and technology from around the world to its state-of-the-art production and R&D facilities spanning over two continents and a wide range of medical equipment.
Skanray is among the biggest teams of biomedical and business specialists in the healthcare industry, with 550 employees.
Facilities & Network
Skanray designs and produces its products in India and Europe, ensuring that customers receive appropriate technological upgrades and service support for the duration of the product’s life cycle.
Skanray has enough replacements on hand for obsolescence management and technological updates to avoid having to replace equipment due to tiny components.
Skanray’s Sales and Service network is one of the most extensive in the business, with over 100 dealers and 50 service franchisees.
Skanray has the greatest uptime in the market because to a vast pool of trained and skilled service engineer specialists.
Aims & Objective
“Nothing is opaque at Skanray” this is their slogan. They are guided by idea of ‘transparency’ in all of its dealings with clients, shareholders, vendors, and business colleagues, in addition to enabling the detection of human anatomical and physiological problems.
Skanray has a fair and clear pricing strategy in place to guarantee that its physicians save time and money so they can devote all of their attention to patient care and treatment.
Technology
Skanray’s strength is its ability to combine diverse technological functions around a core of engineering design and development to produce high-quality goods.
Specialized engineering procedures, product development processes, lean manufacturing techniques, and verification and testing methods are all used to achieve this.
Skanray’s strength is in Product Life Cycle Management for its solutions, which includes everything from idea through design and development, production, after-sales service support, and product.
Skanray Technologies IPO
Skanray technologies, headquartered in Mysore has submitted Draft Red Herring Prospectus(DRHP) to Securities and Exchange Board of India(SEBI) for initial public offering (IPO) of INR 400 crore on 27 June, 2021.
The Offer includes a fresh equity of Rs. 400 crore and an offer for sale(OFS) up to 14,106,347 equity share of face value of 10 per share, by the promoters.
They are now waiting for approval from Securities and Exchange Board of India(SEBI) to float the initial public offering (IPO) in the market.
Financials Trends
| Particulars | For the year/period ended ( in Cr.) | ||||
|---|---|---|---|---|---|
| 31-Dec-20 | 31-Mar-20 | 31-Mar-19 | 31-Mar-18 | ||
| Total Assets | 348.55 | 275.54 | 286.60 | 267.55 | |
| Total Revenue | 350.52 | 153.10 | 166.92 | 141.99 | |
| Profit After Tax | 132.73 | 3.76 | (29.42) | (23.32) | |
Basic and Diluted Earnings Per Share (EPS)
| Financial Period | Basic EPS (in INR) | Diluted EPS (in INR) | Weight |
| Financial Year 2020 | 1.34 | 1.34 | 3 |
| Financial Year 2019 | (10.32) | (10.32) | 2 |
| Financial Year 2018 | (8.98) | (8.98) | 1 |
| Weighted Average | (4.27) | (4.27) | |
| (9 months) Dec. 31, 2020 | 45.75 | 45.75 | – |
Objects of the Issue
- Prepayment / repayment of all or a portion of the outstanding borrowings of the company to be availed on consolidated basis.
- To meet common corporate objectives.
Basis of The offer
- Being a prominent participant in the Indian medical business, it is well positioned to profit from a rising market.
- Product portfolio that is well-diversified and worldwide certified;
- Skills in research and development that have been proven;
- Strengths in production and infrastructure;
- With a large distribution network and long-standing client connections, we have a strategic go-to-market strategy.
- Leadership team with a lot of experience and who knows what they’re doing.
Technology Strengths
- Precise Automated Control of Solid State Power Electronics
- Algorithms for Advanced Radiographic and Fluoroscopic Image Processing Programs
- Networking and data management in hospitals
- Mechanical engineering solutions that focus on usability and are cost-effective
- Thermal management design that works
- Development of biological signal collection, processing, and signal analysis algorithms
- For respiratory management equipment, a precise pneumatics control system is used.
Skanray Technologies IPO Details
| IPO Opening Date | 2021 |
| IPO Closing Date | 2021 |
| Issue Type | Book Building |
| Face Value | 10 per share |
| IPO Price | 0 to 0 per equity share |
| Market Lot | 0 |
| Min Order Quantity | 0 |
| Listing At | BSE, NSE |
| Issue Size | – |
| Fresh Issue | 400 cr. |
| Offer for Sale | 14,106,347 Equity shares |
Skanray Technologies IPO Tentative Date
Skanray Technologies IPO open in 2021, and the close 2021. The issue may list in 2021.
| IPO Open Date | 2021 |
| IPO Close Date | 2021 |
| Basis of Allotment Date | 2021 |
| Initiation of Refunds | 2021 |
| Credit of Shares to Demat Account | 2021 |
| IPO Listing Date | 2021 |
Skanray Technologies IPO Basis of Allotment
| Type | % of Offer | Basis of Allotment |
|---|---|---|
| Qualified Institutional Buyer | 75 |
Roughly
equivalent
|
| Non Institutional Investor | 15 |
Roughly
equivalent
|
| Retail | 10 | Minimum level of 1 lot, based on availability, for every shareholder. |
Skanray Technologies IPO Allotment Status
Allotment of equity stocks subject to the Fresh Issue and transfer of the Promoter Selling Shareholders’ OFS Stocks to the winning Bidders subject to the Offer for Sale. Nevertheless, the status of the allotment has yet to be revealed.
Here, you can find the Allotment Status of Skanray Technologies IPO.
Skanray Technologies IPO GMP
Skanray Technologies IPO Grey market premium is INR 0.
Skanray Technologies IPO Review
Skanray technologies IPO review will depend on the price band. Whenever it will be announced we will update you regarding the IPO is good or bad.
Skanray Technologies IPO Risk
- Others may be able to develop and commercialism technology and solutions substantially similar to theirs if they are unable to obtain, retain, and enforce intellectual property protection for their technology and solutions, or if the scope of their intellectual property protection is not adequately broad, and their ability to effectively commercialise their technology and solutions may be jeopardised.
- They are subject to broad and changing medical device regulation, which may obstruct or delay the approval or sale of their goods and, in certain circumstances, result in the inability to gain clearance for specific items or the recall or seizure of previously approved devices.
Other Threat
- They face fierce competition and may not be able to keep up with the medical device sector’s rapid technical advancements.
- Their growth potential is based on the development of new goods and the enhancement of current products, and a failure to successfully develop and market new products would substantially and adversely affect their company, financial situation, operating performance, and prospects.
- They rely on Their leadership team, and the loss of one or more of their executive officers or important employees, as well as a failure to attract and maintain highly qualified individuals, might threaten their operations.
Skanray Technologies IPO Brokerage views
- Yes Securities : Not Updated
- Choice Brokering: Not Updated
- Axis Securities: Not Updated
- IIFL Securities: Not Updated
- Trade swift: Not Updated
- Anand Rathi : Not Updated
- ICICI Securities: Not Updated
Skanray Technologies IPO Subscription
| Date | Day | QIB | NII | Retail | Employees | Total Subscription |
| 2021 | 1 | |||||
| 2021 | 2 | |||||
| 2021 | 3 |
Skanray Technologies IPO Peer Comparison
Not relevant since there are no publicly traded firms in India that operate in a similar industry to them.
Promoters
- Vishwaprasad Alva
- Agnus Capital LLP
- Chayadeep Properties Limited
- Skanray Healthcare Partners LLP
Skanray Technologies IPO Promoter Holding
| Pre Issue Share Holding | 38.92% |
| Post Issue Share Holding |
Skanray Technologies IPO Prospectus
Contact Details
Skanray Technologies Limited
Plot No 15-17 Hebbal Industrial Area,
Mysore – 570 016, Karnataka, India;
Tel: +91 821 241 5559
E-mail: [email protected]
Website: www.skanray.com
Registrar
Link Intime India Private Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai – 400083
Phone: +91-22-4918 6270
Email: [email protected]
Website: http://www.linkintime.co.in
Lead Manager(s)
- Motilal Oswal Investment Advisors Limited
- Nomura Financial Advisory and Securities (India) Private Limited
- ICICI Securities Limited
We hope we are able to answer all your questions about the Skanray Technologies IPO. If you don’t have a Demat account, open it now with Zerodha best trading app.
clarification
The reference of IPO Grey Market Premium (IPO GMP) is only valid for the date specified in the header.
On the IPO Grey Market, we do not purchase or sell IPO forms.
The Kostak Rate is the profit earned by selling an IPO application (in an off-market transaction) to somebody else before the issue is allotted or listed.
Do not subscribe to an IPO based solely on the premium price, as it may alter at any time before to the listing. Only consider the fundamentals of the companies when subscribing.
The GMP rates for IPOs are based on market intelligence. Please keep in mind that these IPO GMP rates may vary by geography and market.
Note:
We do not engage in grey market trading or facilitate the purchase or sale of IPO forms.
What is grey Market?
The phrase “grey market” refers to an illegal over-the-counter market where IPO applications and IPO stock are traded before the entity is listed on a stock exchange. This is a technique for dealers to help consumers who wish to sell their home before it goes on the market.
This is also a way to increase the listing fee and provide help for the issue prior to the listing. In the IPO grey market, there are two types of transactions that take place:
- IPO stocks are traded at a premium in the grey market.
- At a kostak, an IPO application is traded.
What is grey Market Premium?
The Grey Market Premium, or GMP, is the price at which IPO stock shares are exchanged in the grey market.
This could be correct or incorrect, implying that the grey market trading price is greater or cheaper than the issue price, depending on demand and supply for the stocks.
Typically, individuals who do not want to incur the risk of their shares not being allocated through an IPO can purchase shares on the grey market in the hopes of flipping them on the IPO for a profit.
What is Kostak?
The additional amount in rupees at which IPO applications are sold in the IPO Grey Market is known as kostak (or price of application). The bonus of a maximum lot retail application in an IPO is generally described as the ‘Kostak’ value.
The Kostak price is significant primarily before the offer is closed for subscription and the ultimate bidding status is made accessible to IPO participants. After the final auction status is known to investors, only a small percentage of IPO applications are exchanged.
‘Kostak’ is made for those who do not want to incur a risk on an IPO or gain from a listing.
Example:
Skanray Technologies Limited
Issue Price: Rs 306 Per Equity Share (Maximum Bid price)
Lot Size: 45
Grey Market Premium: Rs 220 to Rs 230
Kostak (Rs 13770): Rs 680 to Rs 720
This means Skanray Technologies ipo applications of Rs 13770 are being traded in IPO Grey Market at Rs 680 to Rs 720.
Despite the fact that this IPO’s Grey Market Premium is roughly 75% of the issue price, the ‘Kostak’ is just 5% of the application value.
Kostak rate
The Kostak rate is the fee received by an investor who sells his or her IPO application on the grey market. Regardless of allotment status, this is the money an individual stands to gain.
Subject to Sauda
The money that an investor stands to gain by selling his or her application for firm allotment is referred to as the subject to Sauda. Firm allocation is the important operative phrase here. The sauda will be cancelled if the applicant is not allotted.
When selling an IPO application in the grey market, the client and seller agree that the sale will only be legal if the seller receives the allocation. The deal is avoided if the seller does not get any stocks throughout the IPO procedure.
FAQ
Skanray Technologies IPO Opening Date?
Skanray Technologies IPO will open on 14 June 2021.
Skanray Technologies IPO Listing Date?
Skanray Technologies IPO will list on 24 June 2021.
Skanray Technologies IPO GMP Today?
Skanray Technologies IPO Grey Market Premium is INR 0.
Skanray Technologies IPO Allotment Date?
Skanray Technologies IPO basis of allotment will be 21 June 2021.
Lot size for Skanray Technologies IPO?
Lot size for Skanray Technologies IPO is 0.
